Drug Profile
Research programme: adult stem cell-based therapy - wounds - Lisata Therapeutics/Boston University School of Medicine
Latest Information Update: 19 Sep 2022
Price :
$50
*
At a glance
- Originator NeoStem
- Developer Boston University School of Medicine; Lisata Therapeutics
- Class Stem cell therapies
- Mechanism of Action Cell replacements; Stem cell stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Wounds
Most Recent Events
- 14 Sep 2022 Cend Therapeutics has merged with Caladrius Biosciences to form Lisata Therapeutics
- 28 Apr 2018 No recent reports of development identified for preclinical development in Wounds in USA
- 30 May 2014 NeoStem and Boston University School of Medicine agree to co-develop adult stem cell-based wound therapy in USA